Llwytho...
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
BACKGROUND: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. METHODS: We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2011
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3549296/ https://ncbi.nlm.nih.gov/pubmed/21639808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1103782 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|